Author | Daniel B. Costa, MD, PhD, MMSc | OncLive

Author | Daniel B. Costa, MD, PhD, MMSc

Articles

Dr. Costa on Biomarkers Beyond PD-L1 for Immunotherapy in NSCLC

April 19, 2017

Video

Daniel B. Costa, MD, PhD, MMSc, associate professor of medicine at Harvard Medical School, medical staff, Hematology/Oncology, medical director of the Cancer Clinical Trials Office, and Medical Center Thoracic Oncology Group Leader, of Beth Israel Deaconess Medical Center, discusses biomarkers beyond PD-L1 in development for immunotherapy in patients with non–small cell lung cancer (NSCLC).

x